Health Care·Life Sciences Tools & Services·$7.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.42 | N/A | -30.00% |
management commentary, guidance changes, and full analysis available with Pro.
| -30.00% |
Tone: Cautiously Optimistic
Overall, management expressed a cautious outlook, focusing on long-term growth despite current hurdles. They reiterated their dedication to improving operational efficiency.
Management highlighted ongoing challenges in the market.
They emphasized their commitment to innovation and product development.
Bio Rad Laboratories reported a lower-than-expected EPS, which indicates some challenges in profitability. However, the stock still saw a slight increase of 0.74%, suggesting that investors may be optimistic about the company's long-term strategies. The lack of revenue data and guidance leaves some uncertainty, but management's focus on innovation could be a positive sign for future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SYSCO CORP
May 2, 2016